| Resumen: |
Objective: To estimate the prevalence and cumulative incidence of neuro-retinal-disorders (NRD) in HIV-controllers. Design: Prospective, single-centre, cohort study of people living with HIV (PLWH): elite-controllers, long-term-non-progressors and early diagnosed. Methods: The study compared "HIV-controllers" (including elite-controllers and long-term-non-progressors), who were not on antiretroviral therapy (ART), and "HIV-treatment" (HIV-infected subjects with a recent diagnosis and on ART). A matched cohort of "non-HIV subjects" was created. NRD was defined as at least one altered (not normal) ophthalmological parameter (functional or structural). Functional (visual acuity, contrast sensitivity, chromatic vision, visual field) and structural parameters (ganglion cells, macular nerve fibre layer, peripapillary nerve fibre layers, vascular calibre) as well as quality of life (Medical Outcomes Study-HIV Short Form-30) were assessed. Results: Between March 2012 and November 2015, the study included all HIV-controllers (16 elite-controllers, 1 long-term-non-progressor), 11 HIV-treatment and 16 non-HIV. Prevalence of NRD at baseline was 88. 2% (15/17, 95% CI: 65. 7%-96. 7%), 90. 9% (10/11, 95% CI: 62. 3%-98. 4%) and 56. 3% (9/16, 95% CI: 33. 2%-76. 9%), respectively. Cumulative incidence at 3 years was 50% (1/2), 100% (1/1) and 33. 3% (2/6), respectively. None of the participants manifested ocular clinical symptoms. Three years later, prevalence of NRD was 92. 3% (12/13, 95% CI: 66. 7%-98. 6%), 75% (6/8, 95% CI: 40. 9%-92. 9%) and 50. 0% (7/14, 95% CI: 26. 8%-73. 2%), respectively. Contrast sensitivity and structural parameters were globally the most affected among PLWH. Quality of life (total score) [median (interquartile range)] at baseline and 3 years was 82 (71-89) and 74 (63. 5-79. 25) in HIV-controllers and 80 (73-88) and 88 (83-92) in HIV-treatment. Conclusions: HIV-controllers and those individuals on ART presented a higher percentage of NRD than non-HIV. Our results suggest that NRD could be a biomarker of ocular aging among PLWH. |
| Nota: |
This work was supported through funds provided by Fight AIDS Foundation (Barcelona, Spain) and the Catalan Ophthalmology Society. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors had full access to the data, and the corresponding author had the final responsibility for submitting the manuscript for publication. |
visitante ::
identificación
(Universitat de Barcelona)
